Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €12.74 EUR
Change Today -0.10 / -0.78%
Volume 383.0K
IPH On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 11:35 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

innate pharma sa (IPH) Snapshot

Open
€12.95
Previous Close
€12.84
Day High
€12.99
Day Low
€12.62
52 Week High
04/27/15 - €17.85
52 Week Low
10/16/14 - €5.94
Market Cap
681.9M
Average Volume 10 Days
590.7K
EPS TTM
€-0.39
Shares Outstanding
53.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INNATE PHARMA SA (IPH)

Related News

No related news articles were found.

innate pharma sa (IPH) Related Businessweek News

No Related Businessweek News Found

innate pharma sa (IPH) Details

Innate Pharma S.A., a biopharmaceutical company, engages in the research and development of pharmaceutical product primarily immunotherapy drugs for cancer and inflammatory diseases in France. The company develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody blocking killer-cell immunoglobulin-like receptors in Phase II clinical trials for cancer and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab; and IPH2201, an IgG4 antibody, which is in Phase I clinical trials for the treatment of rheumatoid arthritis. The company is also involved in the pre-clinical development of IPH4102, a cytotoxic mAb that targets KIR3DL2. In addition, it engages in IPH33 program, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH43 program for the development of anti-MICA therapeutic antibody in oncology. The company has licensing agreements with Bristol-Myers Squibb and Novo Nordisk A/S. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.

99 Employees
Last Reported Date: 03/13/15
Founded in 1999

innate pharma sa (IPH) Top Compensated Officers

Co-Founder, Chairman of Executive Board and C...
Total Annual Compensation: €352.3K
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: --
Member of Executive Board, Senior Advisor Fin...
Total Annual Compensation: €265.5K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: €208.1K
Compensation as of Fiscal Year 2014.

innate pharma sa (IPH) Key Developments

Innate Pharma SA Announces Co-Development and Commercialization Agreement with AstraZeneca Gets HSR Clearance

Innate Pharma SA announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, received HSR clearance. The company also announced that on June 30, Innate Pharma received the initial payment of $250 million from AstraZeneca. The companies will now begin to work together to accelerate and broaden the development of IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Innate Pharma has two clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. Innate Pharma's science also has potential in chronic inflammatory diseases.

The Paoli Calmettes Institute and Innate Pharma S.A. Collaborate on Translational Research for Novel Immune Checkpoint Inhibitors

The Paoli Calmettes Institute initiated a collaboration with Innate Pharma SA to conduct translational research aimed at identifying specific populations of patients with hematological cancers who may benefit most from treatment with Innate Pharma's novel proprietary antibodies, and to identify associated biomarkers. The collaboration will operate under the direction of Pr. Daniel Olive, Head of the Immunity and Cancer research team and of the immune monitoring platform at IPC, and Pascale Andre, Senior Director, R&D, at Innate Pharma. It will also involve drug-discovery research teams and experts in translational research at IPC, including Pr. Norbert Vey and Pr. Anthony Goncalves, and other scientists with expertise in converting promising drug discoveries into clinical treatments for cancer patients. Under the terms of the collaboration agreement, IPC will test Innate Pharma's new therapeutic antibodies in immuno-oncology using IPC's extensive biological resource collection. Innate Pharma's antibodies are designed to block immune checkpoints, one of the most promising classes of drugs in oncology. These immune checkpoints interfere with the natural defense mechanisms of immune system against cancer and regulate immunosuppressive mechanisms. Their blockade can unleash the patient's immune system to recognize and eliminate cancer cells.

Innate Pharma S.A. Presents at Second French Life Science Days Conference, Jun-17-2015

Innate Pharma S.A. Presents at Second French Life Science Days Conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPH:FP €12.74 EUR -0.10

IPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPH.
View Industry Companies
 

Industry Analysis

IPH

Industry Average

Valuation IPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 82.9x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 73.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNATE PHARMA SA, please visit www.innate-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.